Guidance and quality standards Awaiting development

Skip to filters Skip to results

Showing 101 to 150 of 346

Guidance and quality standards awaiting development
Title	Type
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046	Technology appraisal guidance
Electrically stimulated intravesical therapy for Interstitial Cystitis	Interventional procedures guidance
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause TS ID 11917	Technology appraisal guidance
Encorafenib with binimetinib for treating BRAF V600E mutation-positive metastatic non-small-cell lung cancer [ID6177]	Technology appraisal guidance
Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction	Interventional procedures guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer TS ID 10718	Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037	Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]	Technology appraisal guidance
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806	Technology appraisal guidance
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920	Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]	Technology appraisal guidance
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment TS ID 11963	Technology appraisal guidance
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]	Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]	Technology appraisal guidance
Galcanezumab for migraine TS ID 10663	Technology appraisal guidance
Gambling	Quality standard
Gantenerumab for treating early Alzheimer's disease TS ID 10668	Technology appraisal guidance
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394	Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]	Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A TS ID 9772	Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]	Technology appraisal guidance
Gout	Quality standard
Guselkumab for treating moderately to severely active Crohn's disease [ID6238]	Technology appraisal guidance
Guselkumab for treating moderately to severely active ulcerative colitis TS ID 10713	Technology appraisal guidance
Heart valve disease in adults	Quality standard
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]	Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]	Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]	Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies TS ID 10330	Technology appraisal guidance
Image-guided percutaneous laser ablation for primary and secondary liver tumours	Interventional procedures guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990	Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430	Technology appraisal guidance
Infant, children and young people's experience of health care	Quality standard
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]	Technology appraisal guidance
Insulin icodec for treating type 1 and type 2 diabetes TS ID 11770	Technology appraisal guidance
Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention	Interventional procedures guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190	Technology appraisal guidance
Iptacopan for treating complement 3 glomerulopathy TS ID 10435	Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949	Technology appraisal guidance
Isatuximab in combination for newly diagnosed multiple myeloma [ID3981]	Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]	Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]	Technology appraisal guidance
Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux disease	Interventional procedures guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822	Technology appraisal guidance
Leadless cardiac pacemaker implantation for bradyarrhythmias	Interventional procedures guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]	Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996	Technology appraisal guidance

Results per page

10
25
50
All